AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (2 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Full Length Article | Open Access

Phase Ⅰ trial of human umbilical cord-derived mesenchymal stem cells for treatment of severe bronchopulmonary dysplasia

Yunqiu Xiaa,1, Tingyuan Langb,1, Yuqin Niuc, Xian Wud, Ou Zhoue, Jihong Daie, Lei Baof, Ke Yangg, Lin Zouh, Zhou Fue,g( ), Gang Genge( )
Department of Dermatology, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Children’s Hospital of Chongqing Medical University, Chongqing 400014, China
Department of Gynecologic Oncology, School of Medicine, Chongqing University Cancer Hospital, Chongqing University, Chongqing 400030, China
The First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, Xinjiang 832008, China
Department of Respiratory Medicine, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, China
Department of Respiratory Medicine, Children’s Hospital of Chongqing Medical University, Chongqing 400014, China
Department of Neonatology, Children’s Hospital of Chongqing Medical University, Chongqing 400014, China
Chongqing Engineering Technology Research Center of Stem Cell Therapy, Children’s Hospital of Chongqing Medical University, Chongqing 400014, China
Center for Clinical Molecular Medicine, Children’s Hospital of Chongqing Medical University, Chongqing 400014, China

1 These authors contributed equally to this work.

Peer review under responsibility of Chongqing Medical University.

Show Author Information

Abstract

Severe bronchopulmonary dysplasia (BPD) is a chronic lung disorder that primarily affects premature babies with extremely low birth weight and involves in multiple organ system; no effective pharmacotherapy for this disease exists, and mortality remains high. Based on the evidence from previous preclinical studies and phase Ⅰ clinical trials, this study aims to test the safety of intravenous application of a single dose of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) in patients with severe BPD. The Mesenchymal Stem cells for Bronchopulmonary Dysplasia Treatment (MSBDT) trial is a single center, open-label, dose-escalation phase Ⅰ clinical trial. Severe BPD patients were enrolled in Children Hospital of Chongqing Medical University, Chongqing, China. The first six patients were treated with low-dose hUC-MSCs (1 × 106 cells/kg) and the next seven patients were treated with high-dose hUC-MSCs (5 × 106 cells/kg). This study is registered with ClinicalTrials.gov, number NCT03558334. No prespecified infusion-associated adverse events, immediate complication, respiratory or cardiovascular compromise were observed during infusion and 24 h after infusion. No significant changes in safety laboratory values were observed. One death event occurred in the low-dose group on study day 10, and one death event occurred in the high-dose group on study day 24, while, after review in detail, the two cases are not believed to be infusion-associated events. In conclusion, intravenous application of a single dose of hUC-MSCs was tolerated in thirteen patients with severe BPD.

References

【1】
【1】
 
 
Genes & Diseases
Pages 521-530

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Xia Y, Lang T, Niu Y, et al. Phase Ⅰ trial of human umbilical cord-derived mesenchymal stem cells for treatment of severe bronchopulmonary dysplasia. Genes & Diseases, 2023, 10(2): 521-530. https://doi.org/10.1016/j.gendis.2022.02.001

976

Views

7

Downloads

18

Crossref

16

Web of Science

16

Scopus

0

CSCD

Received: 15 December 2021
Revised: 13 January 2022
Accepted: 01 February 2022
Published: 22 February 2022
© 2022 The Authors.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).